Published in Clin Chem on March 17, 2005
Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement. Proc Natl Acad Sci U S A (2011) 1.58
Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol (2009) 1.33
The role of complement in tumor growth. Adv Exp Med Biol (2014) 1.11
Excretion of complement proteins and its activation marker C5b-9 in IgA nephropathy in relation to renal function. BMC Nephrol (2011) 1.08
Discovery and verification of osteopontin and Beta-2-microglobulin as promising markers for staging human African trypanosomiasis. Mol Cell Proteomics (2010) 1.02
Factor h: a complement regulator in health and disease, and a mediator of cellular interactions. Biomolecules (2012) 0.99
Molecular screening for bladder cancer: progress and potential. Nat Rev Urol (2010) 0.97
Complement factor H: a biomarker for progression of cutaneous squamous cell carcinoma. J Invest Dermatol (2013) 0.89
Properdin and factor h: opposing players on the alternative complement pathway "see-saw". Front Immunol (2013) 0.87
Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder. BMC Urol (2006) 0.87
Urine telomerase for diagnosis and surveillance of bladder cancer. Adv Urol (2012) 0.81
Discovery of lung cancer biomarkers by profiling the plasma proteome with monoclonal antibody libraries. Mol Cell Proteomics (2011) 0.81
Gene expression profiling in bladder cancer identifies potential therapeutic targets. Int J Oncol (2017) 0.75
Identification of N-glycosylation in hepatocellular carcinoma patients' serum with a comparative proteomic approach. PLoS One (2013) 0.75
The role of the complement system in cancer. J Clin Invest (2017) 0.75
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol (2010) 3.82
Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol (2005) 3.57
Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney Int (2009) 3.12
New approaches to the treatment of dense deposit disease. J Am Soc Nephrol (2007) 3.02
Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood (2009) 2.97
Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest (2003) 2.96
Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature (2011) 2.64
Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood (2007) 2.46
Monkey malaria in a European traveler returning from Malaysia. Emerg Infect Dis (2008) 2.32
Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol Dis (2005) 2.16
Review of cases with the emerging fifth human malaria parasite, Plasmodium knowlesi. Clin Infect Dis (2011) 2.14
Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res (2010) 2.12
Complement inhibitor factor H binding to Lyme disease spirochetes is mediated by inducible expression of multiple plasmid-encoded outer surface protein E paralogs. J Immunol (2002) 2.06
Factor H family proteins and human diseases. Trends Immunol (2008) 2.02
Successful treatment of DEAP-HUS with eculizumab. Pediatr Nephrol (2013) 2.00
Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol (2007) 2.00
Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol (2013) 1.99
Complement resistance of Borrelia burgdorferi correlates with the expression of BbCRASP-1, a novel linear plasmid-encoded surface protein that interacts with human factor H and FHL-1 and is unrelated to Erp proteins. J Biol Chem (2003) 1.99
An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD). Hum Mol Genet (2010) 1.95
Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood (2008) 1.95
Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration. Mol Immunol (2007) 1.94
Streptococcus pneumoniae evades complement attack and opsonophagocytosis by expressing the pspC locus-encoded Hic protein that binds to short consensus repeats 8-11 of factor H. J Immunol (2002) 1.87
A common site within factor H SCR 7 responsible for binding heparin, C-reactive protein and streptococcal M protein. Eur J Immunol (2003) 1.77
Tumor necrosis factor alpha enhances influenza A virus-induced expression of antiviral cytokines by activating RIG-I gene expression. J Virol (2006) 1.75
Immune evasion of the human pathogen Pseudomonas aeruginosa: elongation factor Tuf is a factor H and plasminogen binding protein. J Immunol (2007) 1.74
Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome. EMBO J (2006) 1.72
Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood (2007) 1.70
Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol (2009) 1.70
Association between complement factor H and proteoglycans in early human coronary atherosclerotic lesions: implications for local regulation of complement activation. Arterioscler Thromb Vasc Biol (2003) 1.68
IFN-alpha enhances TLR3-mediated antiviral cytokine expression in human endothelial and epithelial cells by up-regulating TLR3 expression. J Immunol (2005) 1.67
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther (2009) 1.67
Platelet-associated complement factor H in healthy persons and patients with atypical HUS. Blood (2009) 1.67
Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells. Clin Cancer Res (2010) 1.65
Suicidal death of erythrocytes in recurrent hemolytic uremic syndrome. J Mol Med (Berl) (2006) 1.62
Factor H and atypical hemolytic uremic syndrome: mutations in the C-terminus cause structural changes and defective recognition functions. J Am Soc Nephrol (2005) 1.62
LfhA, a novel factor H-binding protein of Leptospira interrogans. Infect Immun (2006) 1.61
C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int (2008) 1.61
The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models. Hum Mutat (2007) 1.59
Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement. Proc Natl Acad Sci U S A (2011) 1.58
The host immune regulator factor H interacts via two contact sites with the PspC protein of Streptococcus pneumoniae and mediates adhesion to host epithelial cells. J Immunol (2007) 1.58
Glycerol-3-phosphate dehydrogenase 2 is a novel factor H-, factor H-like protein 1-, and plasminogen-binding surface protein of Candida albicans. J Infect Dis (2012) 1.58
Complement resistance mechanisms of streptococci. Mol Immunol (2003) 1.56
Neisserial lipooligosaccharide is a target for complement component C4b. Inner core phosphoethanolamine residues define C4b linkage specificity. J Biol Chem (2003) 1.55
A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res (2012) 1.53
Advances in using PARP inhibitors to treat cancer. BMC Med (2012) 1.49
De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome. Hum Mutat (2006) 1.46
Immune evasion of Borrelia burgdorferi: mapping of a complement-inhibitor factor H-binding site of BbCRASP-3, a novel member of the Erp protein family. Eur J Immunol (2003) 1.45
Upstream conserved sequences of mouse leukemia viruses are important for high transgene expression in lymphoid and hematopoietic cells. Mol Ther (2002) 1.44
Functional characterization of BbCRASP-2, a distinct outer membrane protein of Borrelia burgdorferi that binds host complement regulators factor H and FHL-1. Mol Microbiol (2006) 1.43
Complement regulator-acquiring surface protein 1 imparts resistance to human serum in Borrelia burgdorferi. J Immunol (2005) 1.42
Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site. Am J Pathol (2005) 1.40
Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritis. J Am Soc Nephrol (2012) 1.40
Binding of the complement inhibitor C4bp to serogroup B Neisseria meningitidis. J Immunol (2005) 1.38
Mutations in FN1 cause glomerulopathy with fibronectin deposits. Proc Natl Acad Sci U S A (2008) 1.37
Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity. Mol Cancer Ther (2009) 1.37
Early growth response proteins (EGR) and nuclear factors of activated T cells (NFAT) form heterodimers and regulate proinflammatory cytokine gene expression. Nucleic Acids Res (2003) 1.36
Yersinia enterocolitica serum resistance proteins YadA and ail bind the complement regulator C4b-binding protein. PLoS Pathog (2008) 1.36
Comparative and functional genomics provide insights into the pathogenicity of dermatophytic fungi. Genome Biol (2011) 1.34
The Staphylococcus aureus protein Sbi acts as a complement inhibitor and forms a tripartite complex with host complement Factor H and C3b. PLoS Pathog (2008) 1.34
Streptococcus pneumoniae capsular serotype 19F is more resistant to C3 deposition and less sensitive to opsonophagocytosis than serotype 6B. Infect Immun (2008) 1.33
Complement C3b/C3d and cell surface polyanions are recognized by overlapping binding sites on the most carboxyl-terminal domain of complement factor H. J Immunol (2002) 1.32
The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol (2008) 1.31
Borrelia burgdorferi infection-associated surface proteins ErpP, ErpA, and ErpC bind human plasminogen. Infect Immun (2008) 1.27
Identification and functional characterization of complement regulator-acquiring surface protein 1 of the Lyme disease spirochetes Borrelia afzelii and Borrelia garinii. Infect Immun (2005) 1.27
Autoantibodies in haemolytic uraemic syndrome (HUS). Thromb Haemost (2009) 1.27
Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells. PLoS One (2011) 1.26
Binding of the long pentraxin PTX3 to factor H: interacting domains and function in the regulation of complement activation. J Immunol (2008) 1.23
Where next with atypical hemolytic uremic syndrome? Mol Immunol (2007) 1.23
Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am J Kidney Dis (2005) 1.21
Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome. J Biol Chem (2009) 1.21
Regulation of complement activation at the C3-level by serum resistant leptospires. Microb Pathog (2005) 1.21
γ-H2AX detection in peripheral blood lymphocytes, splenocytes, bone marrow, xenografts, and skin. Methods Mol Biol (2011) 1.20
Lysine-dependent multipoint binding of the Borrelia burgdorferi virulence factor outer surface protein E to the C terminus of factor H. J Immunol (2004) 1.20
Immunological characterization of the complement regulator factor H-binding CRASP and Erp proteins of Borrelia burgdorferi. Int J Med Microbiol (2004) 1.18